306 related articles for article (PubMed ID: 20504106)
21. Long-term golimumab persistence: Five-year treatment retention data pooled from pivotal Phase III clinical trials in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Weinstein CLJ; Meehan AG; Lin J; Briscoe SD; Govoni M
Clin Rheumatol; 2023 Dec; 42(12):3397-3405. PubMed ID: 37751000
[TBL] [Abstract][Full Text] [Related]
22. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study.
Heiberg MS; Koldingsnes W; Mikkelsen K; Rødevand E; Kaufmann C; Mowinckel P; Kvien TK
Arthritis Rheum; 2008 Feb; 59(2):234-40. PubMed ID: 18240258
[TBL] [Abstract][Full Text] [Related]
23. Golimumab: A novel anti-TNF-alpha human monoclonal antibody for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
Campas-Moya C
Drugs Today (Barc); 2010 Jan; 46(1):13-22. PubMed ID: 20200692
[TBL] [Abstract][Full Text] [Related]
24. Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis.
Minozzi S; Bonovas S; Lytras T; Pecoraro V; González-Lorenzo M; Bastiampillai AJ; Gabrielli EM; Lonati AC; Moja L; Cinquini M; Marino V; Matucci A; Milano GM; Tocci G; Scarpa R; Goletti D; Cantini F
Expert Opin Drug Saf; 2016 Dec; 15(sup1):11-34. PubMed ID: 27924643
[TBL] [Abstract][Full Text] [Related]
25. The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.
Furst DE; Kay J; Wasko MC; Keystone E; Kavanaugh A; Deodhar A; Murphy FT; Magnus JH; Hsia EC; Hsu B; Xu S; Rahman MU; Doyle MK
Rheumatology (Oxford); 2013 Oct; 52(10):1845-55. PubMed ID: 23838027
[TBL] [Abstract][Full Text] [Related]
26. MonitorNet: the Italian multi-centre observational study aimed at estimating the risk/benefit profile of biologic agents in real-world rheumatology practice.
Sfriso P; Salaffi F; Montecucco CM; Bombardieri S; Todesco S
Reumatismo; 2009; 61(2):132-9. PubMed ID: 19633800
[TBL] [Abstract][Full Text] [Related]
27. [RETROSPECTIVE DATA ANALYSIS OF THE PATIENTS WITH INFLAMMATORY JOINT DISEASES TREATED WITH GOLIMUMAB IN CROATIA].
Anić B; Babić-Naglić Ð; Grazio S; Kehler T; Kaliterna DM; Radoncić KM; Morović-Vergles J; Novak S; Prus V; Vlak T; Baresić M
Reumatizam; 2015; 62(1):12-9. PubMed ID: 27024887
[TBL] [Abstract][Full Text] [Related]
28. Safety of anti-TNFα agents in the treatment of psoriasis and psoriatic arthritis.
Girolomoni G; Altomare G; Ayala F; Berardesca E; Calzavara-Pinton P; Chimenti S; Peserico A; Puglisi Guerra A; Vena GA
Immunopharmacol Immunotoxicol; 2012 Aug; 34(4):548-60. PubMed ID: 22296031
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of adalimumab treatment in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis.
Poddubnyy D; Rudwaleit M
Expert Opin Drug Saf; 2011 Jul; 10(4):655-73. PubMed ID: 21554150
[TBL] [Abstract][Full Text] [Related]
30. Ten-year drug survival of anti-TNF agents in the treatment of inflammatory arthritides.
Biggioggero M; Favalli EG
Drug Dev Res; 2014 Nov; 75 Suppl 1():S38-41. PubMed ID: 25381973
[TBL] [Abstract][Full Text] [Related]
31. Immunogenicity of golimumab and its clinical relevance in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
Leu JH; Adedokun OJ; Gargano C; Hsia EC; Xu Z; Shankar G
Rheumatology (Oxford); 2019 Mar; 58(3):441-446. PubMed ID: 30412238
[TBL] [Abstract][Full Text] [Related]
32. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study.
Kavanaugh A; McInnes I; Mease P; Krueger GG; Gladman D; Gomez-Reino J; Papp K; Zrubek J; Mudivarthy S; Mack M; Visvanathan S; Beutler A
Arthritis Rheum; 2009 Apr; 60(4):976-86. PubMed ID: 19333944
[TBL] [Abstract][Full Text] [Related]
33. Risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis.
Bonovas S; Minozzi S; Lytras T; González-Lorenzo M; Pecoraro V; Colombo S; Polloni I; Moja L; Cinquini M; Marino V; Goletti D; Matucci A; Tocci G; Milano GM; Scarpa R; Cantini F
Expert Opin Drug Saf; 2016 Dec; 15(sup1):35-54. PubMed ID: 27924644
[TBL] [Abstract][Full Text] [Related]
34. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU;
Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810
[TBL] [Abstract][Full Text] [Related]
35. Clinical inquiries. Are DMARDs effective for rheumatologic diseases besides rheumatoid arthritis?
Goodemote P; Jamieson B; Hoffman R
J Fam Pract; 2007 Nov; 56(11):933-4, 937. PubMed ID: 17976342
[No Abstract] [Full Text] [Related]
36. Novel TNF antagonists for the treatment of rheumatoid arthritis.
Statkute L; Ruderman EM
Expert Opin Investig Drugs; 2010 Jan; 19(1):105-15. PubMed ID: 20001558
[TBL] [Abstract][Full Text] [Related]
37. Effectiveness of psoriatic arthritis therapies.
Gladman DD
Semin Arthritis Rheum; 2003 Aug; 33(1):29-37. PubMed ID: 12920694
[TBL] [Abstract][Full Text] [Related]
38. The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients.
Seitz M; Wirthmüller U; Möller B; Villiger PM
Rheumatology (Oxford); 2007 Jan; 46(1):93-6. PubMed ID: 16720636
[TBL] [Abstract][Full Text] [Related]
39. Golimumab and immunogenicity? 2010 and beyond.
Zidi I; Bouaziz A; Ben Amor N
Pharmazie; 2011 Apr; 66(4):233-43. PubMed ID: 21612149
[TBL] [Abstract][Full Text] [Related]
40. Hospitalizations of patients treated with anti-tumor necrosis factor-α agents -- a retrospective cohort analysis.
Zisman D; Haddad A; Hashoul S; Laor A; Bitterman H; Rosner I; Eder L; Balbir-Gurman A; Mader R; Milman U
J Rheumatol; 2013 Jan; 40(1):16-22. PubMed ID: 23070992
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]